Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Ordinary Shares, nominal value EUR0.05 per share
-
Shares outstanding
-
95,490,450
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
5,703,192
-
Shares change
-
+43,979
-
Total reported value, excl. options
-
$136,879,000
-
Value change
-
+$1,857,397
-
Put/Call ratio
-
463%
-
Number of buys
-
16
-
Number of sells
-
-15
-
Price
-
$24.00
Significant Holders of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) as of Q1 2017
48 filings reported holding CLLS - Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share as of Q1 2017.
Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,703,192 shares
of 95,490,450 outstanding shares and own 6% of the company stock.
Largest 10 shareholders include FMR LLC (3,530,406 shares), ORBIMED ADVISORS LLC (350,000 shares), Tekla Capital Management LLC (310,250 shares), LAZARD ASSET MANAGEMENT LLC (299,034 shares), FRANKLIN RESOURCES INC (243,700 shares), SPHERA FUNDS MANAGEMENT LTD. (159,664 shares), Artal Group S.A. (150,000 shares), Abingworth LLP (100,000 shares), venBio Select Advisor LLC (97,096 shares), and DAFNA Capital Management LLC (76,404 shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.